Cytokinetics Inc
(NAS:CYTK)
$
59.23
-0.91 (-1.51%)
Market Cap: 6.21 Bil
Enterprise Value: 6.44 Bil
PE Ratio: 0
PB Ratio: 0
GF Score: 41/100 Cytokinetics Inc at Barclays Global Healthcare Conference Transcript
Mar 15, 2023 / 07:35PM GMT
Release Date Price:
$37.27
(-1.30%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Good afternoon, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Cytokinetics to the stage. Already had a very exciting start to the year, is just coming off ACC 10 days ago. Joining from the company CEO and President, Robert Blum. Robert, welcome.
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Thanks very much.
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst
Do you want to make some opening comments and then we can get started or just jump into Q&A?
Robert I. Blum
Cytokinetics, Incorporated - CEO, President & Director
Very briefly. This year is a very important year for the company. We are in the midst of a pivot and redeployment and refocusing as is oriented towards aficamten, which is our next-in-class cardiac myosin
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot